EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to atorvastatin

Wei Gao, Xin Guo, Linlin Sun, Jinwei Gai, Yinan Cao, Shuqun Zhang

PeerJ · 2024

DOI: 10.7717/peerj.17749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Wei Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Atorvastatin, Cholesterol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) as the most aggressive molecular subtype of breast cancer is characterized by high cancer cell proliferation and poor patient prognosis. Abnormal lipid metabolism contributes to the malignant process of cancers. Study observed significantly enhanced cholesterol biosynthesis in TNBC. However, the mechanisms underlying the abnormal increase of cholesterol biosynthesis in TNBC are still unclear. Hence, we identified a member of the serine/threonine protein kinase family PKMYT1 as a key driver of cholesterol synthesis in TNBC cells. Aberrantly high-expressed PKMYT1 in TNBC was indicative of unfavorable prognostic outcomes. In addition, PKMYT1 promoted sterol regulatory element-binding protein 2 (SREBP2)-mediated expression of enzymes related to cholesterol biosynthesis through activating the TNF/ TNF receptor-associated factor 1 (TRAF1)/AKT pathway. Notably, downregulation of PKMYT1 significantly inhibited the feedback upregulation of statin-mediated cholesterol biosynthesis, whereas knockdown of PKMYT1 promoted the drug sensitivity of atorvastatin in TNBC cells. Overall, our study revealed a novel function of PKMYT1 in TNBC cholesterol biosynthesis, providing a new target for targeting tumor metabolic reprogramming in the cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAtorvastatinCholesterolHumansFemaleCell Line, TumorGene Knockdown TechniquesGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmSterol Regulatory Element Binding Protein 2Cell ProliferationMembrane ProteinsProtein-Tyrosine KinasesProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

AtorvastatinLipid metabolismPKMYT1TNF/TRAF1/AKT pathwayTriple-negative breast cancer

Substanzen

AtorvastatinCholesterolPKMYT1 protein, humanSterol Regulatory Element Binding Protein 2Membrane ProteinsProtein-Tyrosine KinasesProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Breast Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Day Surgery Center, Dalian Municipal Central Hospital, Dalian, China.
  • Graduate School of Dalian Medical University, Dalian, China.

Zitieren

APA

Gao, W., Guo, X., Sun, L., Gai, J., Cao, Y., & Zhang, S. (2024). PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to atorvastatin. PeerJ. https://doi.org/10.7717/peerj.17749

Vancouver

Gao W, Guo X, Sun L, Gai J, Cao Y, Zhang S. PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to atorvastatin. PeerJ. 2024. doi:10.7717/peerj.17749

BibTeX
@article{Gao2024,
  author = {Gao, Wei and Guo, Xin and Sun, Linlin and Gai, Jinwei and Cao, Yinan and Zhang, Shuqun},
  title = {PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to atorvastatin},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.17749}
}
Kostenlos starten →